Develops drugs for kidney diseases.
Jun 2026Revenue $219M/yrExpenses $234M/yr
No trend
Figures by year
When will Akebia Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $219M and expenses $234M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $236M | $213M | $23.5M |
| Dec 2024 | $160M | $211M | −$50.5M |
| Dec 2023 | $195M | $241M | −$46.3M |
| Dec 2022 | $292M | $373M | −$80.8M |
| Dec 2021 | $212M | $476M | −$265M |
| Dec 2020 | $295M | $672M | −$378M |
| Dec 2019 | $335M | $621M | −$286M |
| Dec 2018 | $208M | $386M | −$178M |
| Dec 2017 | $181M | $258M | −$76.7M |
| Dec 2016 | $1.53M | $138M | −$136M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.